Fecal Transplants Clear Drug-Resistant Bacteria in Over Half of Patients

A groundbreaking study from Chang Gung University in Taiwan offers a new strategy against drug-resistant bacteria, moving beyond the development of stronger antibiotics. Researchers found that fecal microbiota transplantation (FMT) successfully cleared Vancomycin-resistant Enterococci (VRE) – a notoriously difficult-to-treat bacteria – from the gut of over half of high-risk patients, including those with long-term hospital stays, kidney dialysis, or cancer.

The study, approved by Taiwan's Ministry of Health and Welfare, involved transplanting gut bacteria from healthy donors into patients carrying VRE. The results showed that more than 50% of patients achieved VRE clearance after a single treatment, with the positive effects lasting for over six months. This approach aims to restore a healthy gut microbiome, allowing beneficial bacteria to naturally displace resistant strains, rather than relying on increasingly powerful antibiotics.

Dr. Li Po-hsien, director of the Chang Gung Microbiota Treatment Center, explained that FMT is not about using stronger drugs but about re-establishing a balanced gut ecosystem. He noted that while VRE is a significant challenge due to limited treatment options, FMT offers a promising alternative. The treatment has already proven highly effective for Clostridioides difficile infections, boasting a success rate of over 90% compared to 30-40% for traditional antibiotics. Chang Gung has accumulated over 430 cases of FMT treatment for this infection.

“

The concept of microbiota transplantation is not to use stronger antibiotics to kill bacteria, but to re-implant healthy bacteria into the patient's gut, restoring a complete micro-ecosystem.

Beyond VRE and C. difficile, FMT is being explored for a range of other conditions. Research is ongoing into its potential benefits for inflammatory bowel disease, irritable bowel syndrome, obesity, diabetes, and even neurological conditions linked to the gut-brain axis, such as autism, Parkinson's disease, and epilepsy. Preliminary results in these areas have shown promise. Furthermore, international studies suggest FMT might enhance the effectiveness of immunotherapy in certain cancer patients.

Dr. Li emphasized that while FMT is well-supported for C. difficile infections, more clinical evidence is needed for VRE clearance and other diseases. The center aims to develop more personalized microbiota medicine through a comprehensive local gut microbiota database, AI analysis, and microbial testing.

“

Microbiota transplantation is already an important method for treating Clostridioides difficile infections internationally.